FDA approves Keytruda to treat high-risk early-stage triple-negative breast cancer – Merck Inc.
Merck Inc. announced that the FDA has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy… read more.